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ABSTRACT
Poly (ADP-ribose) polymerase (PARP-1), ATM and
DNA-dependent protein kinase (DNA-PK) are all
involved in responding to DNA damage to activate
pathways responsible for cellular survival. Here,
we demonstrate that PARP-1/ cells are sensitive
to the ATM inhibitor KU55933 and conversely that
AT cells are sensitive to the PARP inhibitor
4-amino-1,8-napthalamide. In addition, PARP-1/
cellsareshowntobe sensitive to theDNA-PK inhibitor
NU7026 and DNA-PKcs or Ku80 defective cells
shown to be sensitive to PARP inhibitors. We believe
PARP inhibition results in an increase in unresolved
spontaneous DNA single-strand breaks (SSBs),
which collapse replication forks and trigger homo-
logous recombination repair (HRR). We show that
ATM is activated following inhibition of PARP.
Furthermore, PARP inhibitor-induced HRR is abol-
ished in ATM, but not DNA-PK, inhibited cells. ATM
and DNA-PK inhibition together give the same
sensitivity to PARP inhibitors as ATM alone, indi-
cating that ATM functions in the same pathways as
DNA-PK for survival at collapsed forks, likely in
non-homologous end joining (NHEJ). Altogether,
we suggest that ATM is activated by PARP inhibitor-
induced collapsed replication forks and may function
upstream of HRR in the repair of certain types of
double-strand breaks (DSBs).
INTRODUCTION
Poly (ADP-ribose) polymerase 1 (PARP-1) is an abundant
nuclear protein that binds to a DNA single-strand break
(SSB) and catalyses the formation of PAR polymers on itself
and other acceptor proteins (1). PAR formation is suggested to
be important to protect DNA breaks, alter chromatin structure
and to attract DNA repair proteins to the site of damage (1,2).
PARP-1 is involved in base excision repair (BER) (3), where
interactions between PARP-1 and BER enzymes, such as poly-
merase b (4) and XRCC1 (5) point to a direct role for PARP-1.
PARP-1 has also been associated with homologous recomb-
ination (HR), as lack of PARP-1 leads to increased sister
chromatid exchange and micronuclei formation (3,6). It does
not however appear to be directly required for the process
per se, as Rad51 foci form normally in PARP-1 deficient
cells and an I-SceI induced DNA double-strand break
(DSB) can be repaired normally in PARP inhibited cells (7).
PARP-1 is also thought to be involved in a DNA-PK/Artemis/
XRCC4/ligase IV independent pathway of DSB end joining
repair (8). Here PARP-1 functions with the XRCC1/DNA
ligase III complex and as such could be part of a back up
pathway for non-homologous end joining (NHEJ). Despite
these roles PARP-1 is not essential for cellular survival or
prevention of tumourigenesis since PARP-1 knockout mice
are viable, fertile and do not develop early onset tumours (9).
Presumably due to its function in various DNA repair pro-
cesses, PARP inhibition sensitises cells to multiple DNA-
damaging agents, such as ionising radiation (IR) (10–12),
topoisomerase I inhibitors (13,14) and monofunctional
DNA-alkylating agents (11,14–16). PARP inhibitors therefore
have potential as chemotherapeutics, when used in combina-
tion with many DNA-damaging anti-cancer drugs or radiation
(17). Such combination therapy may be particularly important
in the treatment of tumours with acquired resistance (18,19).
In addition to their role in combined anti-cancer therapies we
and others have recently reported that PARP inhibitors alone
are efficient to treat tumours which are deficient in HR, such as
BRCA2 defective cancers (20,21). We reported that PARP-1 is
important for cellular survival in the absence of homologous
recombination (HR) and demonstrated that this is likely to be
due to the role of PARP-1, together with XRCC1, in SSB
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repair. We proposed that unresolved spontaneous SSBs
in PARP inhibited cells collapse replication forks forming
DSBs which require homologous recombination repair
(HRR) to continue replication.
Here we examine cellular survival following PARP
inhibition in the absence or following inhibition of proteins
also known to be involved in the DNA DSB response, ATM
and DNA-dependent protein kinase (DNA-PK). We show that
survival is decreased when PARP-1 and ATM, DNA-PKcs or
Ku80 are absent or inhibited. In addition, PARP inhibition
causes ATM activation and PARP inhibitor-enhanced HR is
abolished when ATM is inhibited. Altogether, our data suggest
that ATM is required for HRR at collapsed replication forks
produced following PARP inhibition.
MATERIALS AND METHODS
Chemicals
The PARP inhibitor, 4-Amino-1,8-naphthalimide (22), was a
gift from Dr. Nicola Curtin (University of Newcastle, UK) and
the ATM inhibitor, KU55933 (23), and the DNA-PK inhibitor,
NU7026 (24), were kindly donated by Dr Graeme Smith
(KuDOS Pharmaceuticals Ltd, Cambridge, UK). All were
dissolved in DMSO and stored at 20C. Drugs alone or in
combination were added to cell cultures so that the final
DMSO concentrations did not exceed 0.2%.
Cells and cell culture
The A11 and A19 cell lines were a kind gift from Zhao-Qi
Wang (Lyon, France), the AA8 and V3-3 cell lines were
provided by Larry Thompson (Livermore, CA), pEBS-YZ5
and AT221JE-T/pEBS AT cells were generously supplied by
Yoshi Shiloh (Tel Aviv, Isreal), CHO-K1 and XRS6 were
kindly donated by Penny Jeggo (Sussex, UK), GK41 cells
were helpfully supplied by C. Smythe (Sheffield, UK).
All cell lines in this study were grown in DMEM with 10%
Fetal bovine serum and penicillin (100 U/ml) and strepto-
mycin sulphate (100 mg/ml) at 37C under an atmosphere
containing 5% CO2. In addition the SPD8 cell line was
grown in the presence of 5 mg/ml 6-thioguanine.
Recombination assay
A total of 1.5 · 106 cells were inoculated into 100 mm dishes
in media 4 h prior to a 24 h treatment with drugs as indicated or
hydroxyurea (HU) as a positive control. After treatments, the
cells were rinsed three times with PBS and 10 ml media added
before allowing the cells to recover for 48 h. After recovery,
cells were released by trypsinisation and counted. HPRT+
revertants were selected by plating 3 · 105 treated cells per
dish in the presence of HAsT (50 mM hypoxanthine, 10 mM L-
azaserine, and 5 mM thymidine). To determine cloning effici-
ency, two dishes were plated with 500 cells each. The colonies
obtained were stained with methylene blue in methanol (4 g/l),
following 7 (in the case of cloning efficiency) or 10 (for
reversion) days of incubation.
Toxicity assay
A total of 500 or 1000 cells were plated in triplicate onto
100 mm dishes 4 h prior to treatment with combinations of
drugs as indicated. Twelve days later, when colonies could be
observed, they were fixed and stained with methylene blue in
methanol (4 g/l). Colonies consisting of more than 50 cells
were subsequently counted. Each colony was assumed to rep-
resent one cell surviving from the original 500 and surviving
fraction for each dose calculated.
Western blotting
A total of 2 · 106 cells were plated onto 100 mm dishes and
grown for 24 h. Cells were left untreated or treated with
100 mM PARP inhibitor 4-amino-1,8-naphthalimide for times
indicated prior to lysis in RIPA buffer in the presence of 1·
protease and phosphatase inhibitor cocktails (sigma). An
aliquot of 50 mg total protein was then run on a 6 or 10%
SDS–PAGE gel and transferred to Hybond ECL membrane
(Amersham Pharmacia) using a semi-dry transfer cell (Bio-
Rad). This membrane was blocked in 5% milk for 1 h and
immunoblotted with rabbit polyclonal antibodies against
phospho-Ser 1981 ATM (Rockland 1:1000), total ATM
(Oncogene 1:500), phospho-Ser 345 Chk1 (Cell Signaling
1:1000), phospho-Thr 68 Chk2 (Cell Signaling 1:1000),
total Chk2 (Cell Signaling 1:1000) and b-actin (sigma
1:2000) proteins in 5% milk overnight. Anti-rabbit peroxidase
conjugate (Cell Signaling 1:1000) was used as secondary anti-
body and immunoreactive protein was visualized using ECL
reagents (Amersham Pharmacia) following manufacturer’s
instructions.
RESULTS
ATM and DNA-PK promote survival in PARP-1
defective or inhibited cells
PARP-1 mouse knockouts are viable and fertile suggesting
that PARP-1 is not essential (3,25,26). However, double
knockouts of PARP-1 with either ATM or Ku80 are embryonic
lethal (27,28). In contrast, knocking out DNA-PKcs in
PARP-1/ mice is not lethal (29). Instead, such double-
knockout mice revert the severe combined immune defect
normally associated with a DNA-PKcs knockout (29). Here
we tested if chemically inhibiting ATM in the absence of
PARP-1 or inhibiting PARP-1 in the absence of ATM
increased toxicity to each inhibitor in mammalian cells. We
found that PARP-1 defective mouse embryonic fibroblast
(MEF) cells (A11) were more sensitive to the ATM inhibitor
KU55933 than A19 wild-type cells (Figure 1A). Also, ATM
defective AT221JE-T/pEBS cells were more sensitive to the
PARP inhibitor (4-amino-1,8-naphthalimide) than cells
corrected for the AT phenotype by the introduction of the
wild-type ATM cDNA (pEBS-YZ5) (Figure 1B). This sug-
gests that ATM is important to cellular survival following
PARP inhibition.
Similar results were obtained with DNA-PK. A11 cells were
hypersensitive to the DNA-PK inhibitor NU7026 (Figure 2A),
and conversely cells defective in DNA-PK (V3-3) were hyper-
sensitive to PARP inhibition (Figure 2B). In addition XRS6
cells deficient in Ku80 were more sensitive than the relevant
wild-type cell line (CHO-K1). As Ku80 and DNA-PK interact
and both play a role in NHEJ, the sensitivity of V3-3 and
XRC6 is most likely explained by the absence of this pathway.
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These data suggest a role for NHEJ in survival of PARP
inhibited cells. It is interesting to note that Ku80 deficient
cells were more sensitive to PARP inhibition than DNA-PK
deficient cells. This is consistent with embryonic lethality
associated with PARP-1/ Ku80/ double-knockout mice
(28), and survival of PARP-1/ DNA-PKcs/ double-
knockout mice (29).
The wild-type Chinese hamster ovary cell line AA8 was
then treated with different combinations of ATM, DNA-PK
and PARP inhibitors (Figure 3). When both ATM and DNA-
PK were inhibited the cells were more sensitive to PARP
inhibition than non-treated or DNA-PK alone inhibited
cells. However ATM and DNA-PK inhibited cells had a sim-
ilar sensitivity to PARP inhibitors as ATM alone inhibited
cells (Figure 3). As ATM alone inhibited cells show similar
sensitivity to ATM/DNA-PK inhibited cells, they are likely to
function on the same pathway for survival following PARP
inhibition. However as DNA-PK/ATM inhibited cells display
much greater sensitivity than DNA-PK alone inhibited cells,
other ATM dependent processes are likely to contribute fur-
ther to survival following PARP inhibition. After 10 days
exposure to either drug the toxicity to PARP inhibition is
more pronounced than at 24 h (compare Figure 5C to 3).
This suggests that both drugs are active for >24 h. At 24 h
(when both are presumed still active), ATM inhibitor had a
more severe toxicity than the DNA-PK inhibitor thus the dif-
ference in toxicity is not just due to differences in stability but
due to a biological effect. Both the ATM inhibitor (23) and the
DNA-PK inhibitor (24) were used at doses known to fully
inhibit their respective enzyme activity.
Figure 2. Absence of PARP-1 leads to increased sensitivity to DNA-PK
inhibition and vice versa. (A) Survival fraction of A19 (WT) and A11
(PARP-1/) MEFs following treatment for 10 days with increasing doses
of the DNA-PK inhibitor NU7026. (B) Survival fraction of AA8 (WT) and
V3-3 (DNA-PKcs deficient) following treatment for 10 days with increasing
doses of the PARP inhibitor 4-amino-1,8-napthalamide. (C) Survival fraction
of CHO-K1 (WT) and XRS6 (Ku80 deficient) following treatment for 10 days
with increasing doses of the PARP inhibitor 4-amino-1,8-napthalamide.
The means (symbol) and standard deviations (error bar) from at least three
experiments are depicted.
Figure 1. Absence of PARP-1 leads to increased sensitivity to ATM inhibition
and vice versa. (A) Survival fraction of A19 (WT) and A11 (PARP-1/) MEFs
following treatment for 10 days with increasing doses of the ATM inhibitor
KU55933. (B) Survival fraction of AT221JE-T/pEBS (pEBS-ATM defective)
and pEBS-YZ5 (YZ5—corrected for the AT phenotype by wild-type
ATM cDNA) following treatment for 12 days with increasing doses of the
PARP inhibitor 4-amino-1,8-napthalamide. The means (symbol) and standard
deviations (error bar) from at least three experiments are depicted.
Figure 3. Inhibition of ATM and DNA-PK increases sensitivity to PARP
inhibition compared to DNA-PK inhibition alone but not compared to ATM
inhibition alone. Survival fraction of AA8 (WT) cells following treatment for
10 days with/without 10 mM KU55933 (ATM inhibitor), 10 mM NU7026
(DNA-PK inhibitor) or both in combination with increasing doses of the
PARP inhibitor 4-amino-1,8-napthalamide. The means (symbol) and standard
deviations (error bar) from at least three experiments are depicted.
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The ATM kinase is activated following PARP inhibition
As PARP inhibition combined with ATM inhibition seemed
to be detrimental to cells we investigated whether ATM was
activated upon PARP inhibition. Following a 4 h treatment
with PARP inhibitors alone phosphorylation of S1981 on
ATM was detected; phosphorylation then decreased but was
still apparent after 24 h treatment (Figure 4A). This suggests
that one or more of the functions downstream of activated
ATM are required for survival following PARP inhibition.
Both Chk1 and Chk2 are known downstream targets of
ATM (30). Here, we found that only Chk2 was phosphorylated
in response to PARP inhibition (Figure 4B).
ATM is required for PARP inhibitor-induced
homologous recombination repair
Lack of PARP-1 in cells causes increased sister chromatid
exchange, RAD51 foci and micronuclei formation (3,6,31),
suggesting increased levels of HR. In addition, we have pre-
viously demonstrated that PARP inhibitors cause an increase
in gH2AX foci formation, and suggested that these form when
the increased number of SSBs following PARP inhibition,
collapse into DSBs during replication (20). It has been shown
that such collapsed replication forks require HR for repair
(32,33). Here we investigated HR using a cell line (SPD8) (34)
that contains a partial duplication of the hypoxanthine guanine
phosphoribosyl transferase (hprt) gene which leads to expres-
sion of non-functional HPRT protein. HR between the duplic-
ated regions reverts the hprt gene to wild-type and can be
selected for in HAsT media; colonies formed following selec-
tion are therefore indicative of HR (34). Treatment with the
PARP inhibitor 4-amino-1,8-napthalamide caused an increase
in HPRT positive colonies, confirming that PARP inhibition
triggers HRR. Treatment with ATM or DNA-PK inhibitors
alone made no difference to HR levels (Figure 5). However,
co-treatment with the ATM inhibitor prevented the PARP
inhibitor-induced increase in HR back to non-treated back-
ground levels (Figure 5A). DNA-PK inhibition made no dif-
ference to PARP inhibitor-induced HR (Figure 5B). The
cloning efficiency of cells following each treatment was
also determined (Figure 5C) and this was taken into consid-
eration when calculating the recombination frequencies. Thus
the decrease in PARP inhibitor-induced HR seen when ATM
is also inhibited is not due to a difference in survival following
treatment.
A kinase dead dominant negative ATR does not affect
sensitivity to PARP inhibitors
ATR primarily signals at stalled replication forks (35) and may
therefore be implicated in signalling from PARP inhibitor-
induced DNA damage. However we did not see activation
of Chk1, the main downstream target of ATR (36), following
PARP inhibition (Figure 4B). We tested the sensitivity of an
inducible ATR kinase dead dominant mutant cell line (GK41)
to PARP inhibition and found that upon expression of the
dominant dead kinase the sensitivity to PARP inhibitors
although slightly increased was not significantly altered
from wild-type levels (Figure 6). As a positive control the
sensitivity of kinase dead dominant expressing cells to HU
was tested; as reported earlier (37) they were more sensitive
Figure 4. PARP inhibition activates ATM. (A) Western blot for ATM phospho
serine 1981 and ATM control following PARP inhibition for the times indi-
cated. (B) Western blot for CHK1 phospho serine 345, CHK2 phospho threo-
nine 68 and total CHK2 and actin controls following PARP inhibition or 0.5 mM
HU treatment for 24 h.
Figure 5. ATM inhibition prevents PARP inhibitor-induced HR.
(A and B) Recombination frequency in hprt gene following treatment
for 24 h with/without 10 mM KU55933 (ATM inhibitor), 10 mM
NU7026 (DNA-PK inhibitor), 100 mM 4-amino-1,8-napthalamide
(PARP inhibitor), 0.5 mM HU or combinations of the above. (C)
Cloning efficiencies (% of control) of the same cells. The means
(symbol) and standard deviations (error bar) from at least three experiments
are depicted.
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than non-expressing cells (data not shown). These data suggest
that ATR may not play a large role in survival from PARP
inhibitor-induced DNA damage.
DISCUSSION
The ATM/ and PARP-1/ double-knockout mice are
embryonic lethal (27), suggesting that a functional relationship
exists between the two proteins. In agreement with this we
show that AT cells are hypersensitive to a PARP inhibitor and
vice versa that PARP-1/ cells are hypersensitive to a
specific ATM inhibitor, KU55933. In addition, we find that
ATM is phosphorylated following PARP inhibition and that
the downstream target Chk2 is also phosphorylated.
Lack or inhibition of PARP-1 has been shown to increase
gH2AX foci formation, this increase is thought to reflect the
collapse of unresolved spontaneous SSBs into DSBs at rep-
lication forks (20). A collapsed replication fork is therefore
likely to be the substrate that activates ATM in PARP inhibited
cells [it is established that ATM is activated by DSBs (38)].
In support of this, ATM is reported to be activated by the
topoisomerase I inhibitor camptothecin (39), which stabilizes
SSBs that then collapse into DSBs at replication forks (40).
SSBs, when collapsed into DSBs at replication forks, are
the major lesions triggering spontaneous HR (32). Previously
we demonstrated that the HR pathway becomes essential for
survival following inhibition or loss of PARP-1 (20). In our
model, we suggest that loss of repair of spontaneous SSBs in
PARP inhibited cells results in collapsed forks that trigger
HRR (Figure 7). As ATM is also required for survival in
PARP inhibited cells, there might be a relationship between
ATM and HR. A controlling role for ATM in HR has been
suggested (41) and we previously showed that ATM is
required for HRR at slowed replication forks (37). Here, we
find that PARP inhibition-induced HRR does not occur when
ATM is inhibited (Figure 5A). This suggests that an ATM
response is necessary for and may function upstream of HR
during the repair of PARP inhibitor-induced collapsed forks
(Figure 7). Thus, the sensitivity of AT and PARP-1 defective
cells to PARP and ATM inhibitors, respectively, is likely to be
explained by a loss of HRR. However, ATM defective or
inhibited cells do not show the same degree of sensitivity
to PARP inhibitors as do BRCA2 defective cells (20), sug-
gesting that some degree of HRR may proceed at collapsed
forks even in the absence of ATM.
While DSBs associated with replication forks are primarily
repaired with HRR, NHEJ does have an overlapping role in
the repair (33). Thus NHEJ may also become important for
cellular survival following PARP inhibition and subsequent
replication fork collapse. This then could explain why we see
decreased cellular survival in response to PARP inhibitors
when DNA-PKcs or Ku80 are absent or inhibited. It is
interesting to note that specific inhibition of PARP inhibits
DNA-PK activity and vice versa (42) suggesting that PARP-1
can modulate the efficiency of DSB repair in more than one
way effecting both HR and NHEJ.
ATM and DNA-PK inhibition together gave the same sens-
itivity to PARP inhibitors as ATM alone, but an increased
sensitivity compared to DNA-PK inhibitor alone. These
data indicate that ATM and DNA-PK function on the same
pathway and that ATM has additional functions to DNA-PK
in cellular survival following PARP inhibition. It is reported
that in response to IR ATM phosphorylates Artemis which
then process a subset of non-ligatable DNA double-strand
ends with damaged termini prior to NHEJ repair involving
DNA-PK (43). Our data, putting ATM and DNA-PK in the
same survival pathway following PARP inhibition, raise the
possibility that ATM signals to Artemis so that the DNA ends
at a collapsed fork can be repaired by NHEJ. Indeed all the
substrates of endonucleolytic action by Artemis:DNA-PKcs
have been shown to contain transitions of double- and single-
stranded DNA (44). Decreased survival in ATM inhibited
Figure 6. A kinase dead dominant negative ATR does not alter sensitivity
to PARP inhibition. Survival fraction of GK41 cells following treatment for
10 days with increasing doses of the PARP inhibitor 4-amino-1,8-napthalamide
in the presence or absence of 1.5 mg/ml doxycycline to induce expression
of kinase dead dominant negative ATR. The means (symbol) and standard
deviations (error bar) from at least three experiments are depicted.
Figure 7. Model for ATM activation following PARP inhibition. PARP
inhibition results in more collapsed replication forks, probably because
of an inability to efficiently repair endogenous SSBs (20). HR is the most
important pathway for repair of collapsed replication forks in mammalian cells
(32,33) and loss of this pathway results in lethality following PARP inhibition
(20). Our data suggests that the HRR pathway involves an ATM signal, which
would explain the increased sensitivity to PARP inhibitors in AT cells. In
addition our data also imply that a second pathway involving DNA-PK
and ATM is required in survival following PARP inhibition, this is most likely
to be NHEJ.
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cells upon PARP inhibition may therefore, in part, be due to a
lack of NHEJ. The sensitivity of ATM inhibited cells may be
due to its contribution to both NHEJ and HR. The relatively
small increase in sensitivity upon DNA-PK inhibition prob-
ably reflects the relatively small proportion of DSBs at col-
lapsed replication forks which are repaired by NHEJ as
opposed to the majority which are resolved by HR (33).
The absence of Chk1 signal in response to PARP inhibition
and the lack of significant increase in sensitivity to PARP
inhibitors in cells expressing an ATR kinase dead dominant
mutant were unexpected given that ATR normally signals
from lesions which impair replication fork progression (35).
ATR is activated when it binds to regions of ssDNA which are
coated with RPA (45). Maybe chemically inhibiting PARP
leaves it irreversibly bound to DNA ends protecting from
ssDNA formation. Alternately PARP bound to DNA may
prevent RPA from binding and thus ATR from signalling.
In a third scenario the lesion formed by PARP inhibition
may not trigger ATR. This seems less likely as CPT induced
damage (which we believe produces a similar lesion to PARP
inhibition) triggers ATR/Chk1 signalling which protects from
Topo-1 poison induced cell killing (46,47). This surprising
lack of a role for ATR following PARP inhibition will be
the subject of further investigation.
Our data reveals a relationship between PARP-1 and ATM,
and DNA-PK which maybe of value when considering the
therapeutic potential of inhibitors in the treatment of cancer.
Mutations in the ATM gene have been found in T-cell
prolymphocytic leukaemia (48,49), mantle cell lymphoma
(50,51), and B-cell chronic lymphocytic leukaemia (52–55).
Such cases would be ideal candidates for PARP inhibitor
therapy, as the cells containing the ATM mutation would
be expected to be more sensitive to PARP inhibitors than
the surrounding ATM proficient tissue and thus the side effects
usually seen with classical cytotoxic anti-cancer drugs
minimal.
In summary, our data demonstrate that ATM is activated
by PARP inhibition, most likely at collapsed replication
forks, and is required for and may function upstream
of HRR and possibly NHEJ in the repair of certain types
of DSBs.
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